As of right now, the next catalyst I can anticipate is going to be the development of the oral dosage for cUTI. The potential loss of the oral use of Eravacycline is what led to the massive loss in share price from the $50 range down to basically the low single digits. That's where the biggest revenue market exists for the drug.
They said update coming this quarter. Good news on that front can significantly change valuations moving forward.
News 
Market Data 
Discover 
